GSK plc and Medicines for Malaria Venture today announced that the first single-dose of tafenoquine, co-administered with chloroquine for a radical cure, for the prevention of relapse of Plasmodium vivax (P. vivax) malaria, has now been launched in Thailand and Brazil.
In response to the ongoing public health emergency, the government of Brazil accelerated the introduction of tafenoquine in March 2024. The rollout of this new testing and treatment option has begun within the public health system.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
